Acne Vulgaris – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Acne Vulgaris – Pipeline Review, H1 2017’, provides an overview of the Acne Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris

The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects

The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acne Vulgaris

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Allergan Plc

Almirall SA

Biomar Microbial Technologies

BioPharmX Inc

Braintree Laboratories Inc

Brickell Biotech Inc

Cassiopea SpA

Cell Medica Ltd

Cellceutix Corp

Celtaxsys Inc

Common Pharma Inc

Cutanea Life Sciences Inc

Dermira Inc

ELORAC Inc

Ensol Biosciences Inc

Foamix Pharmaceuticals Ltd

Galderma SA

GlaxoSmithKline Plc

Helix BioMedix Inc

Hovione FarmaCiencia SA

Lee's Pharmaceutical Holdings Ltd

LEO Pharma A/S

Novabiotics Ltd

Novan Inc

Novartis AG

Paratek Pharmaceuticals Inc

Pfizer Inc

Phosphagenics Ltd

Photocure ASA

Promius Pharma LLC

Provectus Biopharmaceuticals Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Sol-Gel Technologies Ltd

Sun Pharma Advanced Research Company Ltd

Valeant Pharmaceuticals International Inc

Vectura Group Plc

Vyome Biosciences Pvt Ltd

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Acne Vulgaris - Overview 8

Acne Vulgaris - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Acne Vulgaris - Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Acne Vulgaris - Companies Involved in Therapeutics Development 30

3SBio Inc 30

Allergan Plc 30

Almirall SA 31

Biomar Microbial Technologies 31

BioPharmX Inc 32

Braintree Laboratories Inc 32

Brickell Biotech Inc 33

Cassiopea SpA 33

Cell Medica Ltd 34

Cellceutix Corp 34

Celtaxsys Inc 35

Common Pharma Inc 35

Cutanea Life Sciences Inc 36

Dermira Inc 36

ELORAC Inc 37

Ensol Biosciences Inc 37

Foamix Pharmaceuticals Ltd 38

Galderma SA 38

GlaxoSmithKline Plc 39

Helix BioMedix Inc 39

Hovione FarmaCiencia SA 40

Lee's Pharmaceutical Holdings Ltd 40

LEO Pharma A/S 41

Novabiotics Ltd 41

Novan Inc 42

Novartis AG 42

Paratek Pharmaceuticals Inc 43

Pfizer Inc 43

Phosphagenics Ltd 44

Photocure ASA 44

Promius Pharma LLC 45

Provectus Biopharmaceuticals Inc 45

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 46

Sol-Gel Technologies Ltd 46

Sun Pharma Advanced Research Company Ltd 47

Valeant Pharmaceuticals International Inc 47

Vectura Group Plc 48

Vyome Biosciences Pvt Ltd 48

XBiotech Inc 49

Acne Vulgaris - Drug Profiles 50

(adapalene + clindamycin hydrochloride) - Drug Profile 50

(benzoyl peroxide + tretinoin) - Drug Profile 51

(clindamycin phosphate + tretinoin) - Drug Profile 52

acebilustat - Drug Profile 53

Aczone Combo - Drug Profile 57

aminolevulinic acid hydrochloride - Drug Profile 58

AQ-401 - Drug Profile 59

B-244 - Drug Profile 60

BBI-3000 - Drug Profile 62

benzoyl peroxide - Drug Profile 63

BLI-1100 - Drug Profile 64

brilacidin tetrahydrochloride - Drug Profile 65

carbamide peroxide - Drug Profile 76

CB-0301 - Drug Profile 77

CB-0601 - Drug Profile 80

CJM-112 - Drug Profile 81

CLS-007 - Drug Profile 82

dapsone - Drug Profile 83

DFD-10 - Drug Profile 84

DLX-2323 - Drug Profile 85

DLX-2681 - Drug Profile 86

DMT-210 - Drug Profile 87

DMT-310 - Drug Profile 88

DX-0385 - Drug Profile 89

finasteride - Drug Profile 90

FMX-101 - Drug Profile 91

GSK-1940029 - Drug Profile 94

HB-1345 - Drug Profile 95

Hesed-4000 - Drug Profile 96

IB-07A037 - Drug Profile 97

IDP-120 - Drug Profile 98

IDP-121 - Drug Profile 99

IDP-123 - Drug Profile 100

IDP-126 - Drug Profile 101

IDP-129 - Drug Profile 102

IDP-130 - Drug Profile 103

ingenol disoxate - Drug Profile 104

ivermectin - Drug Profile 106

K-1032 - Drug Profile 107

LTA-001 - Drug Profile 108

methyl aminolevulinate hydrochloride - Drug Profile 109

minocycline - Drug Profile 111

minocycline - Drug Profile 112

minocycline hydrochloride - Drug Profile 116

MTC-896 - Drug Profile 117

olumacostat glasaretil - Drug Profile 119

omiganan pentahydrochloride - Drug Profile 124

Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 126

PF-06423264 - Drug Profile 127

PH-10 - Drug Profile 128

RA-18C3 - Drug Profile 131

sarecycline hydrochloride - Drug Profile 133

SB-204 - Drug Profile 135

SKP-026 - Drug Profile 140

Small Molecule for Acne and Skin Inflammation - Drug Profile 141

Small Molecule to Agonise NR1C3 for Acne Vulgaris - Drug Profile 142

Small Molecules for Acne Vulgaris - Drug Profile 143

Synthetic Peptide for Acne Vulgaris - Drug Profile 144

Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile 145

tazarotene - Drug Profile 146

tretinoin - Drug Profile 147

tretinoin - Drug Profile 149

trifarotene - Drug Profile 150

Vaccine for Acne Vulgaris - Drug Profile 152

VB-1953 - Drug Profile 153

Acne Vulgaris - Dormant Projects 154

Acne Vulgaris - Discontinued Products 159

Acne Vulgaris - Product Development Milestones 160

Featured News & Press Releases 160

Appendix 171

Methodology 171

Coverage 171

Secondary Research 171

Primary Research 171

Expert Panel Validation 171

Contact Us 171

Disclaimer 172

List of Tables

List of Tables

Number of Products under Development for Acne Vulgaris, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acne Vulgaris – Pipeline by 3SBio Inc, H1 2017

Acne Vulgaris – Pipeline by Allergan Plc, H1 2017

Acne Vulgaris – Pipeline by Almirall SA, H1 2017

Acne Vulgaris – Pipeline by Biomar Microbial Technologies, H1 2017

Acne Vulgaris – Pipeline by BioPharmX Inc, H1 2017

Acne Vulgaris – Pipeline by Braintree Laboratories Inc, H1 2017

Acne Vulgaris – Pipeline by Brickell Biotech Inc, H1 2017

Acne Vulgaris – Pipeline by Cassiopea SpA, H1 2017

Acne Vulgaris – Pipeline by Cell Medica Ltd, H1 2017

Acne Vulgaris – Pipeline by Cellceutix Corp, H1 2017

Acne Vulgaris – Pipeline by Celtaxsys Inc, H1 2017

Acne Vulgaris – Pipeline by Common Pharma Inc, H1 2017

Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, H1 2017

Acne Vulgaris – Pipeline by Dermira Inc, H1 2017

Acne Vulgaris – Pipeline by ELORAC Inc, H1 2017

Acne Vulgaris – Pipeline by Ensol Biosciences Inc, H1 2017

Acne Vulgaris – Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Acne Vulgaris – Pipeline by Galderma SA, H1 2017

Acne Vulgaris – Pipeline by GlaxoSmithKline Plc, H1 2017

Acne Vulgaris – Pipeline by Helix BioMedix Inc, H1 2017

Acne Vulgaris – Pipeline by Hovione FarmaCiencia SA, H1 2017

Acne Vulgaris – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Acne Vulgaris – Pipeline by LEO Pharma A/S, H1 2017

Acne Vulgaris – Pipeline by Novabiotics Ltd, H1 2017

Acne Vulgaris – Pipeline by Novan Inc, H1 2017

Acne Vulgaris – Pipeline by Novartis AG, H1 2017

Acne Vulgaris – Pipeline by Paratek Pharmaceuticals Inc, H1 2017

Acne Vulgaris – Pipeline by Pfizer Inc, H1 2017

Acne Vulgaris – Pipeline by Phosphagenics Ltd, H1 2017

Acne Vulgaris – Pipeline by Photocure ASA, H1 2017

Acne Vulgaris – Pipeline by Promius Pharma LLC, H1 2017

Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017

Acne Vulgaris – Pipeline by Sol-Gel Technologies Ltd, H1 2017

Acne Vulgaris – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Acne Vulgaris – Pipeline by Valeant Pharmaceuticals International Inc, H1 2017

Acne Vulgaris – Pipeline by Vectura Group Plc, H1 2017

Acne Vulgaris – Pipeline by Vyome Biosciences Pvt Ltd, H1 2017

Acne Vulgaris – Pipeline by XBiotech Inc, H1 2017

Acne Vulgaris – Dormant Projects, H1 2017

Acne Vulgaris – Dormant Projects, H1 2017 (Contd..1), H1 2017

Acne Vulgaris – Dormant Projects, H1 2017 (Contd..2), H1 2017

Acne Vulgaris – Dormant Projects, H1 2017 (Contd..3), H1 2017

Acne Vulgaris – Dormant Projects, H1 2017 (Contd..4), H1 2017

Acne Vulgaris – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Acne Vulgaris, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports